Two women discussing efruxifermin, or EFX, in front of a whiteboard

Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

PUBLICATIONS SHOULD BE DELIVERED SEPARATELY USING A SPREADSHEET PROGRAM (EXCEL OR SHEETS)

Filter

Feb 2018 | From External Experts

LY2405319, an analog of fibroblast growth factor 21 ameliorates α-smooth muscle actin production through inhibition of the succinate—G-protein couple receptor 91 (GPR91) pathway in mice

Le, C.T., et al PLoS One

Jan 2018 | From External Experts

Structures of β-klotho reveal a ‘zip code’-like mechanism for endocrine FGF signalling

Lee, S., et al Nature

Jan 2018 | FROM EXTERNAL EXPERTS

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

Estes, C. et al. Hepatology

May 2017 | FROM EXTERNAL EXPERTS

A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys

Stanislaus, S. et al. Endocrinology

Apr 2017 | FROM EXTERNAL EXPERTS

FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists

Li, X. et al. Journal of Bone and Mineral Research

Jan 2017 | From External Experts

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

Dulai, P et al Hepatology

Nov 2016 | FROM EXTERNAL EXPERTS

An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function

Lee, J.H. et al. American Journal of Translational Research

Sep 2016 | FROM EXTERNAL EXPERTS

Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-κB signaling pathway

Yu, Y. et al. International Immunopharmacology

Close up of multichannel micropipette filling four small blue centrifuge tubes

We have developed a comprehensive clinical program to evaluate EFX as a potential treatment for MASH.

View Our Pipeline